Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397600 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
A Phase 3 study of Glaucoma and Ocular Hypertension, sponsored by Laboratoires Thea.
- Completed
- Registry status
- Phase 3
- Development phase
- 684
- Enrollment target
- 20
- Study locations
NCT05397600 is a Phase 3 study of Glaucoma and Ocular Hypertension that has completed, run by Laboratoires Thea. The registered enrollment target is 684 participants, below the 903-participant average among 92 other Glaucoma trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT05397600, a Phase 3 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Laboratoires Thea.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 684 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
Conditions Studied
Interventions
- DRUG Bimatoprost Ophthalmic
Study Locations (20)
California
- Velvet Clinical Research - Burbank
- Specialty Eye Care Medical Center - Glendale - Glendale
- Global Research Management, Inc. - Glendale
- Inland Eye Specialists - Hemet - Hemet
- Diabetic Eye Medical Clinic - Inglewood - Inglewood
- Lakeside Vision Center - Irvine - Irvine
- Sage Eyecare - Los Angeles
- Global Vision Eye Care - Los Angeles- Rock Central - Los Angeles
- North Valley Eye Medical Group, Inc. - Mission Hills
- California Eye Specialists Medical Group Inc. - Monrovia - Monrovia
- Aesthetic Eye Care Institute - Eye Research Foundation - Newport Beach
- Foothill Eye Institute - Pasadena - Pasadena
- North Bay Eye Associates - Petaluma - 104 Lynch Creek Way - Petaluma
- California Eye Specialists Medical Group Inc. - Redlands - Redlands
- OC Surgical Eye Institute - Santa Ana
- Santa Barbara Eyecare - Santa Barbara - Santa Barbara
Arizona
- Arizona Eye Center - Chandler - Chandler
- Eye Physicians & Surgeons of Arizona - Glendale Office - Glendale
- Arizona Glaucoma Specialists - Phoenix - Phoenix
- Walman Eye Center - Sun City - Sun City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2022-06-22 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05397600
The ClinicalTrials.gov registry entry for NCT05397600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 903-participant average among 92 other Glaucoma trials with a reported enrollment target (24% lower). The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Bimatoprost Ophthalmic is the first listed.
NCT05397600 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05397600 about?
NCT05397600 is a clinical study titled "Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients". The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
What is the current status of trial NCT05397600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2022-06-22. Estimated completion is 2024-03-07.
What conditions does trial NCT05397600 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT05397600?
The interventions under investigation include: Bimatoprost Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT05397600?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397600 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilocarpine Use After Kahook Goniotomy
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.